<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Warfarin and other VKAs: Dosing and adverse effects</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Warfarin and other VKAs: Dosing and adverse effects</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Warfarin and other VKAs: Dosing and adverse effects</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Russell D Hull, MBBS, MSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David A Garcia, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sara R Vazquez, PharmD, BCPS, CACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 31, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> and other <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> antagonists (VKAs, also called coumarins; eg, <a class="drug drug_general" data-topicid="9159" href="/d/drug information/9159.html" rel="external">acenocoumarol</a>, phenprocoumon, fluindione) have been available for decades and are used in various settings. Their use is challenging because their therapeutic range is narrow and dosing is affected by many factors including genetic variation, drug interactions, and diet. Bleeding risk is higher with warfarin than direct oral anticoagulants (DOACs). However, efficacy of warfarin is greater for certain indications including prosthetic heart valves and antiphospholipid syndrome (APS).</p><p>Time spent outside the therapeutic range further increases the risk of bleeding and/or thromboembolic complications that the VKA was intended to prevent. Nevertheless, these agents have a large body of clinical experience and are highly effective in reducing the risk of venous and arterial thromboemboli in many settings.</p><p>The general principles underlying the clinical use of VKAs, including their complications and laboratory monitoring of the prothrombin time (PT) and international normalized ratio (INR), are reviewed here.</p><p>Separate topics review:</p><p class="bulletIndent1"><span class="glyph">●</span>Interacting medications and medical conditions – (See  <a class="medical medical_review" href="/d/html/1337.html" rel="external">"Biology of warfarin and modulators of INR control"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of warfarin-associated bleeding or supratherapeutic INR – (See  <a class="medical medical_review" href="/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR"</a> and  <a class="medical medical_review" href="/d/html/1325.html" rel="external">"Reversal of anticoagulation in intracranial hemorrhage"</a>.)</p><p></p><p class="headingAnchor" id="H450280"><span class="h1">INDICATIONS AND CONTRAINDICATIONS</span><span class="headingEndMark"> — </span>Indications for VKAs are presented in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atrial fibrillation</strong> – (See  <a class="medical medical_review" href="/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute coronary syndrome</strong> – (See  <a class="medical medical_review" href="/d/html/101.html" rel="external">"Acute coronary syndrome: Oral anticoagulation in medically treated patients"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart failure</strong> – (See  <a class="medical medical_review" href="/d/html/3502.html" rel="external">"Antithrombotic therapy in patients with heart failure"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prosthetic heart valve</strong> – (See  <a class="medical medical_review" href="/d/html/8171.html" rel="external">"Antithrombotic therapy for mechanical heart valves"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stroke</strong> – (See  <a class="medical medical_review" href="/d/html/1119.html" rel="external">"Overview of secondary prevention for specific causes of ischemic stroke and transient ischemic attack"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Deep vein thrombosis</strong> – (See  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary embolism</strong> – (See  <a class="medical medical_review" href="/d/html/95336.html" rel="external">"Venous thromboembolism: Initiation of anticoagulation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiphospholipid syndrome</strong> – (See  <a class="medical medical_review" href="/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome"</a>.)</p><p></p><p>Possible contraindications to the use of anticoagulants are listed in the table  (<a class="graphic graphic_table graphicRef107527" href="/d/graphic/107527.html" rel="external">table 1</a>); however, this list is not intended to substitute for the judgement of the treating clinician, who can assess the risks and benefits for the individual patient.</p><p class="headingAnchor" id="H173518278"><span class="h1">ADVANTAGES AND DISADVANTAGES</span><span class="headingEndMark"> — </span>VKAs have advantages and disadvantages compared with other anticoagulants, and the choice of agent depends on the clinical setting and patient factors. The table  (<a class="graphic graphic_table graphicRef91199" href="/d/graphic/91199.html" rel="external">table 2</a>) summarizes advantages and disadvantages, which include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advantages</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Experience </strong>– There is a large body of clinical experience (including long-term use) and clinician familiarity with use.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Efficacy for selected indications</strong> – Efficacy of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> in greater than DOACs in patients with mechanical heart valves and some patients with antiphospholipid syndrome. (See  <a class="medical medical_review" href="/d/html/8171.html" rel="external">"Antithrombotic therapy for mechanical heart valves"</a> and  <a class="medical medical_review" href="/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Access</strong> – <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> is generally lower cost and wider availability.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Reversal</strong> – There is significant experience with reversing the anticoagulant effect of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, if needed (eg, for serious bleeding), with <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> plus a source of factors II, VII, IX, and X (either Fresh Frozen Plasma [FFP] or prothrombin complex concentrates [PCCs]). However, there is no evidence that this translates to a lower case-fatality rate among patients who experience major anticoagulant-associated bleeding with DOACs. (See  <a class="medical medical_review" href="/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Titration</strong> – <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> carries the option and ability to increase the intensity of anticoagulation with appropriate monitoring when required such as in a subset of patients with antiphospholipid syndrome (APS) who truly "break through" conventional therapeutic range warfarin.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monitoring effect and adherence</strong> – With <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, it is possible to ensure desired anticoagulant effect is achieved, even in patients with advanced kidney disease, patients at extremes of body weight, or patients taking medications that may interact with warfarin. In contrast, there is no routine monitoring for DOACs, and if adherence is low with a DOAC, the patient may not be adequately anticoagulated, but the medical team may not be aware of this.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disadvantages</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Complication rates</strong> – Higher rates of thromboembolic and bleeding complications than direct oral anticoagulants (DOACs) in individuals with atrial fibrillation. (See  <a class="medical medical_review" href="/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a> and  <a class="medical medical_review" href="/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants", section on 'Drug class'</a>.)</p><p></p><p class="bulletIndent2">Increased bleeding risk with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> over DOACs is especially relevant for older adults, which impacts the choice of anticoagulant for many indications. (See <a class="local">'Older adults'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Associated costs and burdens</strong> – Requirement for frequent monitoring, with associated expenses and time requirements (although the ability to monitor international normalized ratio [INR] control may be an advantage for some individuals).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dose changes</strong> – Dosing is affected by illness, changes in diet, and numerous interacting medications. (See  <a class="medical medical_review" href="/d/html/1337.html" rel="external">"Biology of warfarin and modulators of INR control"</a>.)</p><p></p><p class="headingAnchor" id="H21"><span class="h1">WARFARIN ADMINISTRATION</span><span class="headingEndMark"> — </span>The following principles apply to <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> administration and are generally applicable to other VKAs as well.</p><p class="headingAnchor" id="H394780340"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Confirm that <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> is the best choice for the patient. Major indications include mechanical heart valves and antiphospholipid syndrome (APS), especially high-risk APS. A direct oral anticoagulant (DOAC) is preferred for nonvalvular atrial fibrillation or venous thromboembolism (VTE), especially in older adults; older individuals may derive greater safety benefit from a DOAC, as long as cost barriers can be removed. (See <a class="local">'Older adults'</a> below.)</p><p>Some patients may take <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> if they do not have access to a DOAC or if there are other reasons to avoid a DOAC such as concerns about adherence, absorption, kidney or liver function, or DOAC drug interactions. </p><p>Details and specific recommendations are discussed in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prosthetic heart valves</strong> – (See  <a class="medical medical_review" href="/d/html/8171.html" rel="external">"Antithrombotic therapy for mechanical heart valves"</a> and  <a class="medical medical_review" href="/d/html/132746.html" rel="external">"Antithrombotic therapy for surgical bioprosthetic valves and surgical valve repair"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiphospholipid syndrome</strong> – (See  <a class="medical medical_review" href="/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atrial fibrillation</strong> – (See  <a class="medical medical_review" href="/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Venous thromboembolism</strong> – (See  <a class="medical medical_review" href="/d/html/95336.html" rel="external">"Venous thromboembolism: Initiation of anticoagulation"</a> and  <a class="medical medical_review" href="/d/html/95395.html" rel="external">"Venous thromboembolism: Anticoagulation after initial management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other indications</strong> – (See  <a class="medical medical_review" href="/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Settings in which a heparin or vitamin K antagonist may be preferable'</a>.)</p><p></p><p class="headingAnchor" id="H6922379"><span class="h2">Baseline testing</span><span class="headingEndMark"> — </span>Prior to starting <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, it may be appropriate to obtain the following baseline testing, if not already done:</p><p class="bulletIndent1"><span class="glyph">●</span>Baseline prothrombin time (PT) with international normalized ratio (INR) and baseline activated partial thromboplastin time (aPTT). We omit this testing unless there is a clinical reason to obtain it.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count (CBC) including platelet count, to obtain a baseline and identify thrombocytopenia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver function tests, to identify potential alterations of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> metabolism (or hemostasis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urine (or serum) pregnancy test for females of childbearing potential (due to risks of teratogenicity).</p><p></p><p>A decision can also be made regarding whether thrombophilia testing is indicated and when is the ideal time to perform it, taking into account the need for such testing and the potential effects of acute thrombosis and anticoagulant therapy on the results of such testing  (<a class="graphic graphic_table graphicRef76966" href="/d/graphic/76966.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/d/html/1364.html" rel="external">"Screening for inherited thrombophilia in asymptomatic adults"</a> and  <a class="medical medical_review" href="/d/html/5920.html" rel="external">"Thrombophilia testing in children and adolescents"</a> and <a class="local">'Interference with thrombophilia testing'</a> below.)</p><p>Coagulation testing may reveal an underlying thrombophilia such as the antiphospholipid syndrome (APS), which may artifactually increase the PT and/or aPTT, depending on the assay characteristics. Evaluation of abnormalities found upon baseline testing is presented separately. (See  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests"</a> and  <a class="medical medical_review" href="/d/html/6682.html" rel="external">"Approach to the patient with thrombocytosis"</a> and  <a class="medical medical_review" href="/d/html/6680.html" rel="external">"Diagnostic approach to thrombocytopenia in adults"</a>.)</p><p>We suggest not using pharmacogenetic testing (ie, genotyping for polymorphisms that affect <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> or other VKA metabolism or the vitamin K-dependent coagulation factors) to guide initial dosing of the warfarin or other VKAs. Two meta-analyses of randomized trials (both involving approximately 3000 patients) found that dosing incorporating hepatic cytochrome P-450 2C9 (<em>CYP2C9</em>) or <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> epoxide reductase complex (<em>VKORC1</em>) genotype did not reduce rates of bleeding or thromboembolism [<a href="#rid1">1,2</a>]. </p><p>The 2012 American College of Chest Physicians (ACCP) Guidelines also have recommended against the routine use of genotyping for guiding dosing of the VKAs, and the Centers for Medicare and Medicaid Services (CMS) announced a decision in 2009 to decline payment for <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> genetic testing unless administered as part of a clinical trial comparing outcomes in tested and untested patients [<a href="#rid3">3</a>].</p><p>Details of the role of genetic variants in <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> metabolism are presented separately. (See  <a class="medical medical_review" href="/d/html/1337.html" rel="external">"Biology of warfarin and modulators of INR control", section on 'Genetic factors'</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Initial dosing</span><span class="headingEndMark"> — </span>For patients starting <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> therapy, we suggest an initial daily dose of ≤5 mg, rather than higher doses or "loading" doses, unless the patient is known from previous experience to require higher doses.</p><p>The rationale for the avoidance of higher initial doses in most patients comes from several small randomized trials that compared initial doses of 5 versus 10 mg of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, which found that higher doses generally did not result in more rapid therapeutic anticoagulation or improved outcomes, but these higher doses were more likely to lead to a supratherapeutic INR, which can increase the risk of bleeding [<a href="#rid4">4-7</a>]. Additionally, there is a theoretical concern that higher initial doses might cause more dramatic reductions in the anticoagulant factors, protein S and protein C, leading to a greater transient procoagulant state.</p><p>The initial <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> dose is further individualized to take into account factors that may lead to excessive anticoagulation or increased risk of bleeding such as older age, variability in metabolism, and <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> dietary status [<a href="#rid8">8-12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For an otherwise healthy adult, we generally use 5 mg daily on days 1 and 2.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For an adult who is frail, older (&gt;70 to 80 years), malnourished, has liver or kidney disease or heart failure, or is receiving a medication known to increase <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> sensitivity (eg, <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>), we use a lower dose (eg, 2.5 mg daily, 2.5 mg alternating with 5 mg).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Occasionally, a higher initial dose may be appropriate (eg, individual who was previously receiving <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> anticoagulation and required a higher-than-average dose).</p><p></p><p>INR monitoring and appropriate dose adjustment is more important than the number of mgs in the starting dose. The initial dosing strategy presented here is similar to the 2011 British Committee for Standards in Hematology (BCSH), which states that there is no evidence to suggest a 10 mg initial dose is superior to a 5 mg initial dose, and lower doses may be appropriate in older adults [<a href="#rid13">13</a>]. A 2016 Cochrane review of randomized trials comparing an initial <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> dose of 10 versus 5 mg (494 participants) found substantial heterogeneity and no major benefit of starting with 10 versus 5 mg, with individual trials coming to different conclusions about which starting dose resulted in a more rapid therapeutic INR and none of the trials demonstrating differences in bleeding or venous thromboembolism recurrence [<a href="#rid14">14</a>]. Our approach is more consistent with the 2008 ACCP guidelines, which recommend a starting dose of 5 to 10 mg daily, than the 2012 ACCP guidelines, which recommend a starting dose of 10 mg daily [<a href="#rid3">3,15</a>]. The BCSH and ACCP guidelines are updated regularly (available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fb-s-h.org.uk%2Fguidelines%2Fguidelines%2Foral-anticoagulation-with-warfarin-4th-edition&amp;token=S7VxxihlLz%2F68TKEH2ZKHx4UfqN4lD0tbNacJSXPoCBfBd4ZYXTjo8m8IeqTcV5U8QC7wC4sxy7G2jXvdg6v3%2BUX4ssuN9GJIxbgiCcZUd4%3D&amp;TOPIC_ID=1334" target="_blank">https://b-s-h.org.uk/guidelines/guidelines/oral-anticoagulation-with-warfarin-4th-edition</a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fjournal.chestnet.org%2Fguidelines&amp;token=jAuHD9lBZpZp70VcLOyF6Jq95lKCM%2B1j0lrrz34EIbY2epRwWGqANOGVqwoxX5mo&amp;TOPIC_ID=1334" target="_blank">http://journal.chestnet.org/guidelines</a>).</p><p class="headingAnchor" id="H3400470453"><span class="h2">INR-based initial dose adjustment</span><span class="headingEndMark"> — </span>Typically, the PT with international normalized ratio (INR) is measured daily in hospitalized patients and starting on or around day 3 in healthy outpatients. Dosing on day 3 and subsequent days is based on the previous PT and INR results. An example of dose adjustments is provided in the table  (<a class="graphic graphic_table graphicRef101683" href="/d/graphic/101683.html" rel="external">table 4</a>); however, this is not meant to replace a local/institutional algorithm.</p><p>Dosing calculations that incorporate additional clinical variables are sometimes used. The benefit of an automated dosing algorithm was demonstrated in a trial that randomly assigned 13,052 patients from 32 centers to one of two computer-assisted dosage programs (PARMA 5 or DAWN AC) versus dosage determined by the medical staff [<a href="#rid16">16</a>]. The time in target INR range was significantly improved by computer assistance as compared with medical staff dosage, with the greatest advantage being seen at those medical centers with fewer patient-years of experience. However, the overall number of adverse clinical events (eg, bleeding, thrombosis, death) was not significantly reduced (5.5 versus 6 events/100 patient-years for the computer-assisted and medical staff dosage groups, respectively; adjusted incidence rate ratio 0.90, 95% CI 0.80-1.02). An example of an automated dosing calculator is available at <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.warfarindosing.org%2FSource%2FHome.aspx&amp;token=emmKyy2yDV4z6%2BKYhFJGF1QvqYcRg3ihEecLEH8wGnw54o%2BynUAbEvUweM26kX3gpWLkreGJe23muZwsBUqs3Q%3D%3D&amp;TOPIC_ID=1334" target="_blank">www.WarfarinDosing.org/Source/Home.aspx</a> [<a href="#rid17">17</a>].</p><p>Importantly, the INR can increase within two to three days of the first <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> dose, but full anticoagulation generally takes longer (in the range of five to seven days). During the first few days of warfarin therapy, prolongation of the PT/INR mainly reflects depression of factor VII, which has the shortest half-life (four to six hours); however, other vitamin K-dependent factors (eg, factors II [prothrombin], IX, and X) have longer half-lives and are not fully depleted for two to three days  (<a class="graphic graphic_figure graphicRef50940" href="/d/graphic/50940.html" rel="external">figure 1</a>). Thus, for patients with a very high thromboembolic risk, it may be necessary to overlap ("bridge") warfarin with another anticoagulant such as unfractionated or low molecular weight heparin during initiation of warfarin therapy. (See <a class="local">'Transitioning between anticoagulants/bridging'</a> below.)</p><p class="headingAnchor" id="H173517304"><span class="h2">Establishing a maintenance dose</span><span class="headingEndMark"> — </span>Maintenance doses of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> vary significantly from patient to patient, ranging from &lt;2 mg to ≥10 mg per day. Dosing is based on PT/INR readings (see <a class="local">'Monitoring interval'</a> below), with a goal INR that varies with the clinical setting. Typical INR goals are in the range of 2 to 3 in patients with atrial fibrillation or venous thromboembolism and somewhat higher in patients with mechanical heart valves. (See  <a class="medical medical_review" href="/d/html/95395.html" rel="external">"Venous thromboembolism: Anticoagulation after initial management", section on 'Warfarin'</a> and  <a class="medical medical_review" href="/d/html/8171.html" rel="external">"Antithrombotic therapy for mechanical heart valves", section on 'Long-term anticoagulation'</a>.)</p><p>No protocols for adjusting <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> dosing have been uniformly accepted, and dose adjustment practices vary widely [<a href="#rid3">3,5,7,15,18-22</a>]. However, studies suggest that the use of algorithms improves time in the therapeutic range (TTR), an endpoint associated with a lower risk of thromboembolic events and bleeding [<a href="#rid23">23-25</a>]. As described in the ACCP guidelines, decision support through anticoagulation clinics and/or computerized warfarin calculation systems can improve prescribing practices, especially for inexperienced providers [<a href="#rid3">3,15</a>]. (See <a class="local">'Outpatient management'</a> below.)</p><p>Clinicians often tell patients to take <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> in the evening, and this may be useful during initiation of therapy to allow same-day dose corrections to be made based on the INR result. However, a trial that randomly assigned 217 individuals taking warfarin for at least three months to take their dose in the morning or the evening found that switching to morning dosing did not have a statistically significant effect on the TTR [<a href="#rid26">26</a>]. Patients should take their dose at whichever time fosters the best adherence.</p><p>A reasonable approach to adjusting <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> dosing is outlined in the warfarin dosing protocol used in patients with atrial fibrillation enrolled on the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial  (<a class="graphic graphic_table graphicRef87435" href="/d/graphic/87435.html" rel="external">table 5</a>) [<a href="#rid23">23</a>]. Important aspects of this protocol include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>This protocol only applies to patients already taking <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> and should not be used during the first week of therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The interval for PT/INR monitoring depends on the stability of measured values, dose requirements, and clinical status.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The monitoring interval can be extended once a maintenance dose has been established and the PT/INR remains in the therapeutic range. (See <a class="local">'Monitoring interval'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>More frequent monitoring (eg, once or twice weekly) is appropriate for patients with a PT/INR outside the therapeutic range. More frequent monitoring is also appropriate if changes occur that could alter <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> absorption, metabolism, or anticoagulant effect (intercurrent illness, initiation of a new interacting medication, change in diet). (See  <a class="medical medical_review" href="/d/html/1337.html" rel="external">"Biology of warfarin and modulators of INR control"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The effect of dose changes may take up to three days to be reflected in the PT/INR. Thus, significant dose changes generally should be made only based on PT/INR results obtained at least two days after a previous dose adjustment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients whose INR is only slightly outside the target range, repeat testing in a week without dose adjustment may be the best course of action. As an example, an observational study and modeling that predicted better INR control could be achieved by changing the dose when the INR is ≤1.7 or ≥3.3 (predicted TTR of 74 percent versus predicted TTR of 68 percent when changing the dose for INR ≤1.8 or ≥3.2) [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional interventions may be appropriate for patients with poor PT/INR control. (See <a class="local">'Poor INR control/vitamin K supplementation'</a> below.)</p><p></p><p>A post hoc analysis of 6022 patients in the RE-LY trial evaluated outcomes according to whether <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> dose adjustments were consistent with the proposed algorithm [<a href="#rid28">28</a>]. As compared with patients taking warfarin who did not have algorithm-consistent dosing, patients who did have algorithm-consistent dosing spent more days with their PT/INR in the therapeutic range (13 versus 22 percent of days). The patients with algorithm-consistent dosing also experienced a lower incidence of stroke, embolism, or bleeding. While the use of the algorithm likely varied by center, the improvements in clinical outcomes did not appear to be due to other center variations in patient care since these outcomes did not differ among centers in patients in the original RE-LY trial who were assigned to treatment with <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a>.</p><p>Factors that may affect individual maintenance dosing include nutritional status; <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> intake; hepatic, renal, and cardiac function; acute illnesses; medication adherence, drug-drug interactions  (<a class="graphic graphic_table graphicRef62697" href="/d/graphic/62697.html" rel="external">table 6</a>), and genetic variation [<a href="#rid29">29-32</a>]. These factors are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1337.html" rel="external">"Biology of warfarin and modulators of INR control"</a>.)</p><p class="headingAnchor" id="H173516236"><span class="h2">Outpatient management</span><span class="headingEndMark"> — </span>Outpatient management of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> may be supervised by hospital or community-based clinicians, anticoagulation clinics, or a self-management program. Monitoring used for this management may be performed at a laboratory or with a self-monitoring device (point-of-care device). (See <a class="local">'Self-monitoring and self-management'</a> below.)</p><p>A 2018 guideline from the American Society of Hematology recommended patient self-monitoring using a POC device and self-adjusted dosing over other approaches for those individuals who have demonstrated competence in self-testing and can afford the associated costs [<a href="#rid33">33</a>]. In general, management through an anticoagulation clinic or self-management is associated with better outcomes than individual clinician management in the community, as described below. The choice between these options will depend on clinician and patient resources and preferences. (See <a class="local">'Anticoagulation clinics'</a> below and <a class="local">'Self-monitoring and self-management'</a> below.)</p><p>Regardless of the management approach, studies have demonstrated that patient education and availability of a clinician to review medication changes and answer questions results in fewer bleeding complications, reduced hospitalization costs, and greater patient satisfaction. This was demonstrated in a prospective cohort study involving 2346 patients receiving <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> who had 126 hospitalizations due to warfarin-related bleeding over a two-year follow-up period [<a href="#rid34">34</a>]. Compared with those who did not receive educational materials, those who did receive instruction had a reduced rate of bleeding (incidence rate ratio [IRR] 0.40, 95% CI 0.24-0.68). The likelihood of bleeding was increased in those who had four or more clinicians providing prescriptions (IRR 2.4, 95% CI 1.2-4.6).</p><p>Several studies have addressed the cost-effectiveness of various management approaches [<a href="#rid35">35-42</a>]. In general, the most cost-effective programs are those that reduce the number of emergency department visits and/or hospitalizations for hemorrhage or thromboembolism.</p><p>Artificial intelligence-based tools to guide dosing changes are under investigation [<a href="#rid43">43-45</a>]. These are not standard of care and do not substitute for management by an experienced human using an evidence-based dosing approach.</p><p class="headingAnchor" id="H173516313"><span class="h3">Anticoagulation clinics</span><span class="headingEndMark"> — </span>Anticoagulation clinics are dedicated sites or services that provide testing and management of outpatient anticoagulation. Monitoring can be done with a point-of-care device on-site or through a laboratory. Dose changes can be managed by individuals with a variety of backgrounds including pharmacists, nurses, and physicians.</p><p>These clinics have the advantages of providing consistent provider interactions; opportunities to review patient medications, dietary changes, and clinical status; and ongoing patient education [<a href="#rid46">46</a>]. They can also provide routine reminders for upcoming and missed appointments, and documentation for PT/INR measurements and dose changes [<a href="#rid47">47-49</a>]. Often, algorithms or programs for calculating dose adjustments are used, which eliminates variability in dosing changes. Randomized trials have demonstrated that management of anticoagulation by hospital-based anticoagulation clinics is at least as good as routine hospital follow-up and marginally better than management directed by family physicians [<a href="#rid50">50,51</a>].</p><p>Examples of available data include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A multicenter trial randomly assigned 10,421 patients to management using a new version of the PARMA 5 computer program versus manual dose change by experienced medical staff [<a href="#rid52">52</a>]. Overall number of major bleeds, thrombotic events, and death were similar in the two groups. The time in the therapeutic range (TTR) for the computer-assisted and manual approaches was 66 and 65 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A systematic review and meta-analysis of randomized and nonrandomized trials compared management by a pharmacist-participated management program versus usual care in 728,377 individuals receiving <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid36">36</a>]. Compared with usual care, pharmacist management was associated with a reduction in total bleeding (relative risk [RR] 0.51, 95% CI 0.28-0.94). However, major bleeding, thromboembolic events, and mortality were not significantly different.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective cohort study compared management by telephone versus face-to-face encounters in 234 patients receiving <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid53">53</a>]. There were no significant differences in bleeding, thrombosis, emergency department visits, or hospital admissions between the groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2021 systematic review and meta-analysis involving over 8000 patients found that, compared to in-person management, telepharmacy management was associated with lower risks of any bleeding (RR 0.65, 95% CI 0.47-0.90) and hospitalization (RR 0.59, 95% CI 0.39-0.87) and no statistically significant difference in TTR, supratherapeutic INR, major or minor bleeding, or thromboembolic events [<a href="#rid54">54</a>].</p><p></p><p class="headingAnchor" id="H173516501"><span class="h3">Self-monitoring and self-management</span><span class="headingEndMark"> — </span>Small portable devices are available for patients to measure their own degree of anticoagulation (eg, in-home measurement of PT/INR). When accompanied by appropriate education and training, along with consistent quality control, the majority of patients, including older adults, can effectively and safely adjust their anticoagulant dosing [<a href="#rid55">55-62</a>]. The PT/INR values obtained with these devices generally correlate well with laboratory measurements  (<a class="graphic graphic_figure graphicRef52321" href="/d/graphic/52321.html" rel="external">figure 2</a>).</p><p>Guidance from the BCSH suggests individuals using these devices should [<a href="#rid42">42</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Receive appropriate training and education in operating the monitor and managing <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> dosing.</p><p class="bulletIndent1"><span class="glyph">●</span>Should keep accurate records of PT/INR results and dose adjustments.</p><p class="bulletIndent1"><span class="glyph">●</span>Should verify the accuracy of readings with standard laboratory testing at least every six months and if results are unexpectedly high or low or if there are concerns about storage conditions of the test strips. </p><p></p><p>Several systematic reviews and meta-analyses of randomized trials have concluded that appropriately trained patients who used self-monitoring and/or self-adjustment of VKA therapy had as good or better outcomes than those who used anticoagulation clinics or community-based management [<a href="#rid40">40,63-66</a>]. As an example, a 2016 meta-analysis of randomized trials compared self-monitoring and/or self-adjustment in 8950 individuals [<a href="#rid66">66</a>]. Compared with controls, individuals who used self-monitoring and/or self-adjusted dosing had the following outcomes over a follow-up period of 3 to 57 months.</p><p class="bulletIndent1"><span class="glyph">●</span>Fewer thromboembolic events (RR 0.58, 95% CI 0.45-0.75)</p><p class="bulletIndent1"><span class="glyph">●</span>No difference in major or minor bleeding events (RR 0.95, 95% CI 0.8-1.12 and RR 0.97, 95% CI 0.67-1.41, respectively)</p><p class="bulletIndent1"><span class="glyph">●</span>A nonsignificant trend toward reduced mortality (RR 0.85, 95% CI 0.71-1.01)</p><p></p><p>The largest trial included in this meta-analysis, <strong>T</strong>he <strong>H</strong>ome <strong>INR</strong> <strong>S</strong>tudy (THINRS), randomly assigned 2922 patients using <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> for a cardiac indication (atrial fibrillation, mechanical valve) to self-monitoring alone (without self-management) versus management in an anticoagulation clinic [<a href="#rid67">67</a>]. In this trial, clinical outcomes were similar, and the time to the first primary event (stroke, major bleeding episode, or death) was not significantly longer in the self-testing group than in the anticoagulation clinic-testing group (hazard ratio [HR] 0.88, 95% CI 0.75-1.04). The self-testing group had a small but significant improvement in the percent of time in the therapeutic range (TTR) for the PT/INR (absolute difference 3.8 percentage points) as well as small but significant improvements in patient satisfaction and quality of life.</p><p>Self-monitoring is not feasible for all patients and requires patient education and ability to use the device as well as an underlying institutional policy for providers of this service [<a href="#rid40">40,64,68</a>]. Approximately 80 percent of patients eligible for the THINRS trial (2931 of 3643) were able to demonstrate competency in using a home monitoring device [<a href="#rid69">69</a>]. Factors associated with inability to use the device included older age, prior stroke, impaired cognition, and reduced manual dexterity.</p><p>Some self-monitoring devices may give erroneous results in patients with an antiphospholipid antibody, as may some laboratory-based tests [<a href="#rid70">70</a>]. In this setting, the readings from the self-monitoring device should be compared with results of chromogenic testing of factor Xa activity. (See <a class="local">'Interference with thrombophilia testing'</a> below.)</p><p class="headingAnchor" id="H704753410"><span class="h2">Drug interactions</span><span class="headingEndMark"> — </span>VKAs have numerous drug interactions that may warrant a change in therapy or increased PT/INR monitoring; these are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1337.html" rel="external">"Biology of warfarin and modulators of INR control", section on 'Drug interactions'</a>.)</p><p class="headingAnchor" id="H635336"><span class="h2">Warfarin resistance</span><span class="headingEndMark"> — </span>The term "<a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> resistance" has been used by some clinicians for patients who require very high doses of warfarin to attain a therapeutic PT/INR. We prefer to avoid this term, as it implies a specific clinical entity, when in fact a variety of factors may impact warfarin dose requirements (eg, diet, metabolism, interacting medications).</p><p>A separate issue is a patient who has a thromboembolic event while receiving <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> despite a therapeutic PT/INR. Management of such patients is discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent venous thrombosis – (See  <a class="medical medical_review" href="/d/html/95395.html" rel="external">"Venous thromboembolism: Anticoagulation after initial management"</a> and  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent stroke – (See  <a class="medical medical_review" href="/d/html/1059.html" rel="external">"Stroke in patients with atrial fibrillation", section on 'Anticoagulation failure'</a>.)</p><p></p><p>There is no evidence that very large daily doses of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> confer additional toxicity or unanticipated side effects other than those listed below (see <a class="local">'Complications'</a> below), as long as the INR is in the therapeutic range.</p><p class="headingAnchor" id="H2456861"><span class="h2">Warfarin discontinuation</span><span class="headingEndMark"> — </span>For patients discontinuing <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, the medication may be stopped abruptly; a taper is not required [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H633998"><span class="h1">MONITORING (PT/INR)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> anticoagulation requires monitoring to determine the degree of anticoagulation and to guide dose adjustments to optimize the time in the therapeutic range, which is a surrogate for clinical outcomes. </p><p>For the vast majority of patients, monitoring is done using the prothrombin time with international normalized ratio (PT/INR), which reflects the degree of anticoagulation due to depletion of vitamin K-dependent coagulation.</p><p>The mechanism by which <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> prolongs the PT/INR is discussed separately. (See  <a class="medical medical_review" href="/d/html/1337.html" rel="external">"Biology of warfarin and modulators of INR control", section on 'Mechanism of action'</a>.)</p><p>It is worth noting that the PT/INR in a patient on <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> may not reflect the total anticoagulation status of the patient in certain settings:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>First few days of </strong><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a><strong> initiation</strong> – (See <a class="local">'Initial dosing'</a> above and  <a class="medical medical_review" href="/d/html/1337.html" rel="external">"Biology of warfarin and modulators of INR control", section on 'Biology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver disease</strong> – (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'Laboratory abnormalities'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Baseline prolonged PT/INR</strong> (eg, lupus anticoagulant) – (See  <a class="medical medical_review" href="/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome", section on 'Anticoagulant monitoring'</a>.)</p><p></p><p class="headingAnchor" id="H173515147"><span class="h2">Monitoring interval</span><span class="headingEndMark"> — </span>The frequency of monitoring is determined by the stability of the PT/INR values over time and changes in clinical status.</p><p class="bulletIndent1"><span class="glyph">●</span>Hospitalized patients generally have the PT/INR monitored daily because a variety of factors during hospitalization may affect <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> absorption and/or metabolism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients initiating anticoagulation with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, or transitioning between warfarin and another anticoagulant, require frequent measurements (eg, daily, every other day, two to three times per week) in accordance with institutional protocols.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Those with a PT/INR outside the therapeutic range, or those with frequent dose adjustments or change in clinical status, require more frequent monitoring until the dose can be stabilized (eg, two or more times per week, or weekly).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Once the anticoagulant effect and patient's <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> dose requirements have been stabilized for at least one to two weeks, the INR can be monitored less frequently, at intervals in the range of every two to four weeks [<a href="#rid15">15,71</a>]. Monitoring once every four weeks is often used.</p><p></p><p class="bulletIndent1">Patients who have had repeatedly therapeutic, stable INRs may be monitored less frequently [<a href="#rid72">72-74</a>], and the 2012 American College of Chest Physician (ACCP) Guidelines and 2018 American Society of Hematology (ASH) Guidelines have suggested an INR testing frequency of up to 12 weeks for patients with consistently stable INRs [<a href="#rid3">3,33</a>]. However, we generally monitor more frequently than every 12 weeks in all but the most stable patients with clinical features similar to those in clinical trial populations.</p><p></p><p>Importantly, additional dose changes generally are not made until the patient has had a repeat PT/INR determination after two or more days at a new dose because changes in dose generally are not reflected immediately. (See <a class="local">'Establishing a maintenance dose'</a> above.)</p><p>Serial monitoring of the INR will detect many patients who are over-anticoagulated before they have had a bleeding episode. However, monitoring is not completely protective because there may be only a brief warning period during which a slightly elevated INR predicts for an imminent bleeding event. This was illustrated in a review of 32 patients with a warfarin-related hemorrhage in whom the mean INR at the time of bleeding was 5.9, but the mean INR at the most recent routine measurement, obtained an average of 12 days before the bleeding event, was 3.0 [<a href="#rid75">75</a>]. Additionally, many cases of warfarin-associated bleeding occur in the setting of a therapeutic INR. (See  <a class="medical medical_review" href="/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Mitigating bleeding risk'</a>.)</p><p class="headingAnchor" id="H637106"><span class="h2">Importance of strict INR control</span><span class="headingEndMark"> — </span>The intensity of anticoagulation correlates well with clinical outcomes. This has been demonstrated in various systematic reviews, meta-analyses, and other studies [<a href="#rid24">24,76-79</a>]. In a meta-analysis of 45 studies involving 71,065 individuals receiving a VKA, one-half of the thromboembolic events occurred when the international normalized ratio (INR) was below the therapeutic range, and 44 percent of hemorrhages occurred when the INR was above the therapeutic range [<a href="#rid80">80</a>]. This relationship is illustrated in the figures for patients with atrial fibrillation  (<a class="graphic graphic_figure graphicRef65373" href="/d/graphic/65373.html" rel="external">figure 3</a>) and other conditions  (<a class="graphic graphic_figure graphicRef78252" href="/d/graphic/78252.html" rel="external">figure 4</a>).</p><p>The quality of INR control is often assessed by determining the percentage of the time in the therapeutic range (TTR), a measure that can be estimated from a period of INR readings or calculated by an interpolation method. (See  <a class="medical medical_review" href="/d/html/1337.html" rel="external">"Biology of warfarin and modulators of INR control", section on 'Overview of INR control'</a>.)</p><p>In general, a TTR of 65 to 70 percent is considered to be good quality control [<a href="#rid81">81,82</a>]. A study in patients with atrial fibrillation found that adding <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> to antiplatelet therapy led to improved outcomes when the TTR was &gt;60 percent, but the benefit was lost with TTR approximately &lt;60 percent [<a href="#rid83">83</a>].</p><p>The relative efficacy of various approaches for maximizing the TTR was addressed in a systematic review and meta-regression of 67 studies involving 50,208 patients followed for a total of 57,155 patient-years [<a href="#rid84">84</a>]. The PT/INR was in the therapeutic range an average of 64 percent of the time, and the rate varied with study setting:</p><p class="bulletIndent1"><span class="glyph">●</span>Self-management – 72 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Randomized trials – 66 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Anticoagulation clinics – 66 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Community practices – 57 percent</p><p></p><p>Self-management, which yielded the highest percent of time spent within the therapeutic INR range, is not feasible in all situations but is often associated with a high TTR. This approach may be preferable for patients who place a high value on being able to control their testing and dosing. However, this approach is not feasible for all patients; it requires the capability to self-monitor and make dose adjustments, along with institutional policy, appropriately trained providers, and educational resources. (See <a class="local">'Self-monitoring and self-management'</a> above.)</p><p>As noted above, the time of day <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> is taken does not appreciably affect the TTR once the individual's dose has been established. The time of day that would result in the best adherence should be used. (See <a class="local">'Establishing a maintenance dose'</a> above.)</p><p>Importantly, for patients with a suboptimal TTR, it is important to determine whether the variability in PT/INR measurements is due to factors such as diet or medication interactions, which might be improved by low-dose <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> supplementation (see <a class="local">'Poor INR control/vitamin K supplementation'</a> below) or by using a different oral anticoagulant; or to patient noncompliance, which may argue against the use of one of the direct oral anticoagulants because of their shorter half-lives and lack of validated monitoring. (See <a class="local">'Advantages and disadvantages'</a> above.)</p><p class="headingAnchor" id="H173524773"><span class="h2">Poor INR control/vitamin K supplementation</span><span class="headingEndMark"> — </span>Two major factors that may lead to poor control of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> dosing and may be modified by relatively straightforward interventions are failure to take warfarin appropriately and very low dietary <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> intake/vitamin K deficiency.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medication adherence</strong> – A variety of factors may reduce VKA adherence including confusion about dosing, delays in communication with the treating clinician, and challenges of taking a different dose on different days of the week (see  <a class="medical medical_review" href="/d/html/1337.html" rel="external">"Biology of warfarin and modulators of INR control"</a>). Patient education programs have been shown to improve the TTR in most settings, as discussed above. (See <a class="local">'Outpatient management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">Vitamin K</a><strong> status</strong> – In some cases, poor INR control may be due to low dietary vitamin K intake or vitamin K deficiency, both of which may make the patient especially sensitive to small day-to-day variations in vitamin K intake. Some populations may be at greater risk for vitamin K deficiency (eg, poor nutrition). Administration of a small daily dose of vitamin K has been tested in several studies and one published randomized trial [<a href="#rid85">85</a>]. A 2016 systematic review that included 15 studies (1838 patients) concluded that the use of daily vitamin K at a very small dose (range, 100 to 500 mcg daily) may be associated with a clinically relevant improvement in the TTR, but there is no clinically relevant benefit to using this approach in unselected populations receiving <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid86">86</a>]. The dose must be sufficient to blunt large changes in the international normalized ratio (INR) but low enough that it does not interfere with anticoagulation. In the published trial, 70 patients with unexplained poor INR control were randomly assigned to receive 150 mcg of daily vitamin K or placebo for six months [<a href="#rid87">87</a>]. Compared with controls, individuals receiving low-dose vitamin K had less variability in PT/INR measurements and the increase in the TTR was greater (28 versus 15 percent). Additional studies also suggest that low-dose oral vitamin K, in the range of 100 to 200 mcg orally per day, may improve INR control [<a href="#rid88">88</a>]. This intervention may be appropriate for patients with suspected vitamin K deficiency for whom other interventions to improve anticoagulation status are ineffective, which may particularly apply to those with low dietary vitamin K intake (eg, older individuals with a limited diet or poor nutrition).</p><p></p><p class="bulletIndent1">There are no low-dose oral formulations of <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> approved by the US Food and Drug Administration (FDA); however, several formulations are available from health food stores and pharmacies [<a href="#rid89">89</a>]. A pharmacist can help the patient locate a vitamin K1 oral 100 mcg supplement from a highly reliable, nationally known supplier that adheres to good manufacturing practices and standards.</p><p></p><p class="bulletIndent1">In contrast to patients with poor INR control, for other patients receiving a VKA there is no evidence to support routine <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> supplementation [<a href="#rid3">3</a>].</p><p></p><p class="headingAnchor" id="H634141"><span class="h2">Falsely elevated INRs</span><span class="headingEndMark"> — </span>The most common cause of a falsely elevated international normalized ratio (INR) is the presence of heparin in the blood sample. This can be avoided by obtaining the needed blood sample from a peripheral vein rather than from indwelling central venous catheters, which might be contaminated with heparin.</p><p>Another common cause of a falsely elevated INR is inadequate filling of pediatric collection tubes, resulting in a higher than normal ratio of citrate anticoagulant to patient plasma. (See  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Sample collection and handling'</a>.)</p><p>The presence of a lupus anticoagulant may also artificially prolong the PT/INR value. Approaches to monitoring <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> in this setting are presented separately. (See  <a class="medical medical_review" href="/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome", section on 'Anticoagulant monitoring'</a>.)</p><p class="headingAnchor" id="H622653915"><span class="h2">Other monitoring strategies (investigational)</span><span class="headingEndMark"> — </span>The INR is based on the PT, and the PT is highly sensitive to the vitamin K-dependent factor with the shortest half-life (factor VII). Thus, minor fluctuations in factor VII levels can cause the PT and INR to shift in and out of range. However, the main mechanism of action of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> is likely to be via its effects on factors II and X. </p><p>A new strategy for <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> monitoring has been proposed that depends on the levels of factor II and factor X rather than factor VII, referred to as the factor II and X prothrombin time (Fiix-PT; pronounced "fix-PT"); a corresponding Fiix-normalized ratio (Fiix-NR) can also be calculated [<a href="#rid90">90</a>]. In a comparison of thrombosis and bleeding rates in 2667 individuals stably anticoagulated with warfarin who had been managed based on the PT and INR, substitution of the Fiix-PT assay and Fiix-NR-based dose adjustments resulted in a lower thrombosis rate and a reduction in the number of laboratory tests and dose adjustments:</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombosis – Reduced from 2.8 percent to 1.2 percent per patient-year (p = 0.02)</p><p class="bulletIndent1"><span class="glyph">●</span>Bleeding – Unchanged at 2.8 percent </p><p class="bulletIndent1"><span class="glyph">●</span>Number of laboratory tests – Reduced from 17 to 13 per patient-year</p><p class="bulletIndent1"><span class="glyph">●</span>Number of dose adjustments – Reduced from 5.0 to 3.3 per patient-year </p><p></p><p>The assay uses test plasma deficient in factors II and X and can be automated using diluted patient plasma samples. An editorialist noted that these real-world results confirm findings from an earlier small trial and suggested that implementation of the Fiix-PT and Fiix-NR should become a high priority [<a href="#rid91">91</a>]. </p><p class="headingAnchor" id="H7574832"><span class="h1">TRANSITIONING BETWEEN ANTICOAGULANTS/BRIDGING</span><span class="headingEndMark"> — </span>The goal when transitioning between anticoagulants is to maintain stable anticoagulation. Thus, when transitioning <strong>from</strong> another anticoagulant <strong>to</strong> a VKA, it is important to keep in mind that the full effect of the VKA does not occur for the first few days, despite prolongation of the prothrombin time/international normalized ratio (PT/INR) [<a href="#rid92">92,93</a>] (see <a class="local">'Initial dosing'</a> above). Likewise, when transitioning from <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> to another anticoagulant, the resolution of warfarin effect may take several days.</p><p>The following approaches are reasonable when transitioning from another anticoagulant to <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> or another VKA but do not substitute for clinical judgement regarding individual patient factors.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heparin products/</strong><a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a><strong>/</strong><a class="drug drug_general" data-topicid="8765" href="/d/drug information/8765.html" rel="external">argatroban</a><strong> to </strong><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> – The parenteral agent and the VKA are overlapped for at least five days, and for at least 24 hours or two consecutive days after the PT/INR has reached the therapeutic range [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Direct oral anticoagulants (DOACs [</strong><a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a><strong>; </strong><a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a><strong>, </strong><a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">edoxaban</a><strong>, </strong><a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a><strong>]) to </strong><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> – The anticoagulants are overlapped, since it takes several days for warfarin to become therapeutic (including two to three days after the INR reaches the target range). In cases of very high thromboembolic risk, a parenteral agent may be used during the transition from the DOAC to warfarin. The direct factor Xa inhibitors (apixaban, edoxaban, and rivaroxaban) also prolong the PT/INR, which may make monitoring during the transition more challenging; thus, it may be helpful to check the INR at the approximate trough of the DOAC dose. Specific instructions from the product information and society guidelines are discussed in a separate topic review. (See  <a class="medical medical_review" href="/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Transitioning between anticoagulants'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a><strong> to heparin/</strong><a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a><strong>/</strong><a class="drug drug_general" data-topicid="8765" href="/d/drug information/8765.html" rel="external">argatroban</a> – Start the parenteral agent when the INR is &lt;2. (See  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'Bridging anticoagulation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a><strong> to a DOAC</strong> – Discontinue the VKA, monitor the PT/INR, and start the DOAC when the INR is below a certain threshold (between 2 and 3, with slight variations depending on the package information for each agent, as summarized in a separate topic review). In general, we think it is reasonable to discontinue VKA and initiate a DOAC when the INR is ≤2. (See  <a class="medical medical_review" href="/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Transitioning between anticoagulants'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>One VKA to another VKA</strong> – When transitioning between VKAs, discontinue the old VKA and begin the new VKA at the next scheduled dose, assuming the PT/INR is in the therapeutic range. The PT/INR should also be monitored more frequently when substitution of one <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> preparation for another has occurred in order to screen for differences in drug availability [<a href="#rid95">95-97</a>].</p><p></p><p>Aspects of anticoagulant discontinuation and initiation specific to individual clinical settings are discussed in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atrial fibrillation</strong> – (See  <a class="medical medical_review" href="/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants", section on 'Other reasons for switching agents'</a> and  <a class="medical medical_review" href="/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prosthetic heart valve</strong> – (See  <a class="medical medical_review" href="/d/html/104830.html" rel="external">"Anticoagulation for prosthetic heart valves: Management of bleeding and invasive procedures", section on 'Planning for invasive procedures'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Venous thromboembolism</strong> – (See  <a class="medical medical_review" href="/d/html/95395.html" rel="external">"Venous thromboembolism: Anticoagulation after initial management", section on 'Switching anticoagulants during therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perioperative management</strong> – (See  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal procedures</strong> – (See  <a class="medical medical_review" href="/d/html/2609.html" rel="external">"Management of anticoagulants in patients undergoing endoscopic procedures"</a>.)</p><p></p><p class="headingAnchor" id="H435545"><span class="h1">COUNSELING AND PATIENT EDUCATION</span></p><p class="headingAnchor" id="H435551"><span class="h2">Dietary considerations</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> efficacy is affected by changes in dietary <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> intake. Importantly, this should not be interpreted to mean that patients should eliminate vitamin K from the diet. Rather, patients must pay attention to their dietary vitamin K intake and attempt to maintain a relatively stable level of intake over time. (See  <a class="medical medical_review" href="/d/html/1337.html" rel="external">"Biology of warfarin and modulators of INR control"</a>.)</p><p>Patients should be provided with information regarding the <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> content of foods and other sources (eg, vitamins)  (<a class="graphic graphic_table graphicRef78708" href="/d/graphic/78708.html" rel="external">table 7</a> and <a class="graphic graphic_table graphicRef65279" href="/d/graphic/65279.html" rel="external">table 8</a>) and advised to maintain a relatively consistent level of intake rather than told to avoid vitamin K-containing foods. (See  <a class="medical medical_review" href="/d/html/1337.html" rel="external">"Biology of warfarin and modulators of INR control", section on 'Vitamin K intake'</a>.)</p><p>The use of low-dose <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> supplementation in patients with poor international normalized ratio (INR) control is discussed above. (See <a class="local">'Poor INR control/vitamin K supplementation'</a> above.)</p><p class="headingAnchor" id="H435631"><span class="h2">Alcohol and smoking</span><span class="headingEndMark"> — </span>Patients taking <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> are advised about the possibility of variable INR control with excessive alcohol intake or "binge" drinking; however, patients do not need to abstain from alcohol because they are taking warfarin. (See  <a class="medical medical_review" href="/d/html/1337.html" rel="external">"Biology of warfarin and modulators of INR control", section on 'Tobacco, marijuana, and alcohol'</a>.)</p><p>Tobacco may affect <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> efficacy, especially smokeless tobacco, which has a high <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> content. Patient education regarding tobacco cessation is a component of routine medical care; the anticoagulation provider should be notified about changes in tobacco use as this may affect the INR. (See  <a class="medical medical_review" href="/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p class="headingAnchor" id="H435649"><span class="h2">Sports participation</span><span class="headingEndMark"> — </span>Use of an anticoagulant is associated with an increased risk of trauma-associated bleeding. Guidelines are not available to assist patients taking <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> in determining which sports activities are to be avoided and which are acceptable. Patients who elect to participate in activities with a greater than average risk for blunt trauma should be aware that taking warfarin increases the likelihood that any given injury may be complicated by serious bleeding [<a href="#rid98">98,99</a>].</p><p class="headingAnchor" id="H38"><span class="h1">COMPLICATIONS</span></p><p class="headingAnchor" id="H624064"><span class="h2">Bleeding</span><span class="headingEndMark"> — </span>Factors that affect bleeding risk and an approach to the management of warfarin-associated bleeding or supratherapeutic international normalized ratio (INR) are presented in detail separately. (See  <a class="medical medical_review" href="/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants"</a> and  <a class="medical medical_review" href="/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR"</a> and  <a class="medical medical_review" href="/d/html/1325.html" rel="external">"Reversal of anticoagulation in intracranial hemorrhage"</a>.)</p><p>The safety benefit of a direct oral anticoagulant (DOAC) over <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> may be greatest for older individuals, especially those with other risk factors for bleeding. (See <a class="local">'Older adults'</a> below.)</p><p class="headingAnchor" id="H39"><span class="h2">Skin necrosis</span><span class="headingEndMark"> — </span>Skin necrosis has been reported in some patients within the first few days of receiving large doses of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid100">100</a>]. The skin lesions usually occur in areas with subcutaneous fat, including the extremities, breasts, trunk, or penis. Skin changes marginate over a period of hours from an initial central erythematous macule  (<a class="graphic graphic_picture graphicRef80462" href="/d/graphic/80462.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef62792" href="/d/graphic/62792.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef51999" href="/d/graphic/51999.html" rel="external">picture 3</a>). Biopsies demonstrate fibrin thrombi within cutaneous vessels and associated interstitial hemorrhage.</p><p>Skin necrosis appears to be mediated by the rapid reduction of protein C levels on the first day of therapy, which induces a transient hypercoagulable state. Approximately one-third of patients who develop these lesions have underlying hereditary protein C deficiency; however, among patients with protein C deficiency, skin necrosis is an infrequent complication of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> therapy [<a href="#rid101">101</a>].</p><p>In an individual with known protein C deficiency, approaches to anticoagulation include using a non-warfarin anticoagulant or providing a parenteral agent for the first few days of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> therapy until a stable PT/INR has been reached. Individuals without a diagnosis of protein C deficiency who are treated with warfarin for venous thromboembolism will receive another anticoagulant initially to achieve rapid anticoagulation for the acute event, whereas those with atrial fibrillation who are treated with warfarin prophylactically for stroke prevention generally are treated as an outpatient and do not receive another anticoagulant during the first few days of warfarin.</p><p>Case reports have also described skin necrosis or thrombosis at other sites in association with an acquired functional deficiency of protein C or protein S, heterozygous protein S deficiency, or the factor V Leiden mutation [<a href="#rid102">102</a>]. (See  <a class="medical medical_review" href="/d/html/1354.html" rel="external">"Protein C deficiency", section on 'Warfarin-induced skin necrosis'</a>.)</p><p class="headingAnchor" id="H41"><span class="h2">Teratogenicity during pregnancy</span><span class="headingEndMark"> — </span>VKAs are known teratogens and are generally contraindicated during at least the first trimester of pregnancy. This subject is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum", section on 'Warfarin teratogenicity'</a>.)</p><p class="headingAnchor" id="H42"><span class="h2">Cholesterol embolization</span><span class="headingEndMark"> — </span>Embolization of cholesterol crystals (cholesterol microembolism) is a rare complication of anticoagulation with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>. Typically, this occurs after several weeks of therapy and may present as a dark, purplish, mottled discoloration of the plantar and lateral surfaces of the lower extremities. This condition has been variously called "blue toe syndrome" or "purple toe syndrome" [<a href="#rid103">103-105</a>]. (See  <a class="medical medical_review" href="/d/html/8184.html" rel="external">"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)", section on 'Skin'</a>.)</p><p class="headingAnchor" id="H1217599869"><span class="h2">Vascular calcification</span><span class="headingEndMark"> — </span>A number of studies have suggested that the chronic use of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> may lead to arterial calcification (eg, aortic valve, coronary arteries, femoral artery) [<a href="#rid106">106-109</a>]. As an example, in a series of 157 patients with atrial fibrillation who had calcium scans, coronary calcium scores increased significantly with the duration of VKA use, from a mean score of 53 in patients not receiving a VKA to a mean score of 236 in patients receiving a VKA for over five years [<a href="#rid109">109</a>]. The mechanism may involve inhibition of a <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> dependent matrix Gla protein. (See  <a class="medical medical_review" href="/d/html/1318.html" rel="external">"Vitamin K-dependent clotting factors: Gamma carboxylation and functions of Gla", section on 'Function of Gla in bone, connective tissue, and vascular proteins'</a>.)</p><p>These observations notwithstanding, there is no evidence that <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> increases the risk of clinical events that would be expected in patients with increased calcification of the arterial wall such as stroke, myocardial infarction, or peripheral vascular disease. (See  <a class="medical medical_review" href="/d/html/5297.html" rel="external">"Coronary artery calcium scoring (CAC): Overview and clinical utilization"</a>.)</p><p class="headingAnchor" id="H771902470"><span class="h2">Nephropathy</span><span class="headingEndMark"> — </span>Anticoagulant-related nephropathy (also called warfarin-related nephropathy) refers to acute kidney injury that occurs in the setting of excessive anticoagulation; its existence as a distinct entity is difficult to establish with certainty. The pathogenesis, risk factors, evaluation, and management are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/91030.html" rel="external">"Anticoagulant-related nephropathy"</a>.)</p><p class="headingAnchor" id="H12437430"><span class="h2">Allergic reactions</span><span class="headingEndMark"> — </span>Allergy to <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> (which may be related to the dye in the tablet) is extremely rare although the frequency is unknown. Cross-allergy between coumarin derivatives has been described, but details are limited. In a case report, a single patient developed a maculopapular rash following treatment with three different coumarin derivatives [<a href="#rid110">110</a>].</p><p>The paucity of information concerning the safety of switching from one coumarin derivative to another because of an allergic reaction is such that the clinician will need to make clinical decisions on a case-by-case basis. The possibility that the patient is reacting to the dye in the tablet (rather than the coumarol moiety itself) should always be considered. In cases of suspected dye allergy, it may be prudent to use a dye-free tablet (such as a 10 mg dye-free <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> tablet).</p><p class="headingAnchor" id="H625499"><span class="h2">Interference with thrombophilia testing</span><span class="headingEndMark"> — </span>Genetic testing for inherited thrombophilia (eg, prothrombin G20210A mutation, factor V Leiden mutation) can be performed during VKA use; however, it is not possible to reliably test protein S or protein C levels in a patient receiving a VKA because these proteins are vitamin K-dependent  (<a class="graphic graphic_table graphicRef76966" href="/d/graphic/76966.html" rel="external">table 3</a>). Some lupus anticoagulant assays will yield false positive results in patients receiving a VKA.</p><p>Importantly, these caveats for thrombophilia testing should not be interpreted to imply that this testing is performed routinely prior to <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> initiation. Indications for thrombophilia testing are discussed separately. (See  <a class="medical medical_review" href="/d/html/1363.html" rel="external">"Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors"</a> and  <a class="medical medical_review" href="/d/html/1083.html" rel="external">"Overview of the evaluation of stroke", section on 'Blood tests'</a>.)</p><p class="headingAnchor" id="H173522193"><span class="h1">SPECIAL SITUATIONS</span></p><p class="headingAnchor" id="H173522200"><span class="h2">Conception/pregnancy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> is a known teratogen (see <a class="local">'Teratogenicity during pregnancy'</a> above). Strategies for anticoagulation of females receiving warfarin around the time of conception and in the setting of a prosthetic heart valve are presented separately. (See  <a class="medical medical_review" href="/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum", section on 'Warfarin-associated bleeding'</a> and  <a class="medical medical_review" href="/d/html/8126.html" rel="external">"Management of antithrombotic therapy for a prosthetic heart valve during pregnancy"</a>.)</p><p class="headingAnchor" id="H173522243"><span class="h2">Surgery</span><span class="headingEndMark"> — </span>Depending upon the type of surgery planned, anticoagulation with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> may have to be interrupted temporarily. This subject is discussed separately. (See  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a> and  <a class="medical medical_review" href="/d/html/104830.html" rel="external">"Anticoagulation for prosthetic heart valves: Management of bleeding and invasive procedures", section on 'Planning for invasive procedures'</a>.)</p><p>Rapid reversal of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> in patients who require urgent/emergent surgery is also discussed separately. (See  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'Urgent/emergency invasive procedure'</a>.)</p><p class="headingAnchor" id="H3530204771"><span class="h2">Older adults</span><span class="headingEndMark"> — </span>Bleeding risk and thrombotic risk both tend to increase with increasing age, but there is no upper age limit above which anticoagulation cannot be used [<a href="#rid111">111,112</a>]. Several studies have documented that appropriate anticoagulation has been prescribed at too low a dose or not prescribed at all to older individuals [<a href="#rid113">113-116</a>].</p><p>However, because bleeding risks increase with age, especially with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, experts recommend that older individuals use a direct oral anticoagulant (DOAC) for most indications, including venous thromboembolism and atrial fibrillation. The safety benefit of a DOAC over warfarin may be especially relevant for older individuals with other risk factors for bleeding. (See  <a class="medical medical_review" href="/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants", section on 'Risk factors for bleeding'</a>.)</p><p>The 2023 updated Beers criteria from the American Geriatric Society (AGS) recommend that patients ≥65 years of age not initiate <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> for venous thromboembolism (VTE) or nonvalvular atrial fibrillation unless there are contraindications to using a DOAC or substantial barriers to DOAC use [<a href="#rid117">117</a>]. According to these criteria, individuals ≥65 years who have been using warfarin long-term with well controlled INR (&gt;70 percent of the time in the therapeutic range) without adverse effects may reasonably continue warfarin. </p><p>The following may be useful when prescribing <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> to older individuals:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age cutoff</strong> – There is no clear age cutoff that defines "older"; features of aging that increase bleeding risk in some individuals may not be relevant in others (eg, changes in diet, polypharmacy). The Beers criteria use ≥65 years to define an older adult [<a href="#rid117">117</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – As a general rule, older individuals have increased sensitivity to the anticoagulant effect of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> at any given dose [<a href="#rid118">118-121</a>]. Thus, older individuals are likely to require a lower mean daily dose to maintain the international normalized ratio (INR) in the appropriate range. In one report, individuals ≥75 years needed less than one-half the daily warfarin dose of those &lt;35 years for an equivalent INR [<a href="#rid122">122</a>]. A slightly lower warfarin starting dose (eg, 3 to 5 mg daily) is reasonable, and, as noted above, "loading" doses are to be avoided. (See <a class="local">'Initial dosing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions</strong> – Older individuals may be more likely to be prescribed multiple medications, sometimes from multiple providers. It is thus especially important to educate patients about the potential drug-drug interactions and to monitor the INR more closely (eg, once per week) when a new medication that may affect the INR is added. This is especially important for new antibiotics. (See  <a class="medical medical_review" href="/d/html/1337.html" rel="external">"Biology of warfarin and modulators of INR control", section on 'Drug interactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Concomitant antiplatelet agents</strong> – Combined use of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> and antiplatelet agents may further increase bleeding risk by interfering with two mechanisms of hemostasis (platelets and coagulation factors). (See  <a class="medical medical_review" href="/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants", section on 'Concomitant antiplatelet medications'</a>.)</p><p></p><p class="bulletIndent1">This may be especially relevant in individuals with atrial fibrillation who develop an acute coronary syndrome. Appropriate use of triple antithrombotic therapy is discussed separately. (See  <a class="medical medical_review" href="/d/html/1535.html" rel="external">"Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy"</a> and  <a class="medical medical_review" href="/d/html/101.html" rel="external">"Acute coronary syndrome: Oral anticoagulation in medically treated patients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Shared decision-making</strong> – The increased risks of bleeding and thrombosis in older individuals highlight the need for patient education, understanding of the risks, and consideration of patient values and preferences. As an example, many clinicians are more concerned about the risk of fatal intracerebral bleeding, whereas many patients are more fearful of the chronic, devastating effects of a thrombotic stroke. For individuals with atrial fibrillation, the use of risk scores to estimate bleeding and thrombotic risk may be helpful in ensuring that the clinician and the patient have similar information about overall risks and modifiable risk factors. These risk scores are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a> and  <a class="medical medical_review" href="/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Mitigating bleeding risk'</a> and  <a class="medical medical_review" href="/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants"</a>.)</p><p></p><p class="headingAnchor" id="H173522283"><span class="h2">Resumption after bleeding</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> may be safely reinitiated in selected patients following a bleeding event. Considerations regarding whether and when to resume warfarin after bleeding are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>After intracerebral hemorrhage (ICH) – (See  <a class="medical medical_review" href="/d/html/129071.html" rel="external">"Spontaneous intracerebral hemorrhage: Secondary prevention and long-term prognosis", section on 'Anticoagulation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After an endoscopic procedure – (See  <a class="medical medical_review" href="/d/html/2609.html" rel="external">"Management of anticoagulants in patients undergoing endoscopic procedures", section on 'Resuming anticoagulants after hemostasis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After other bleeding – (See  <a class="medical medical_review" href="/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Resumption of anticoagulation after bleeding'</a>.)</p><p></p><p class="headingAnchor" id="H4140037604"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114614.html" rel="external">"Society guideline links: Anticoagulation"</a>.)</p><p class="headingAnchor" id="H45"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/16265.html" rel="external">"Patient education: Choosing an oral medicine for blood clots (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/86638.html" rel="external">"Patient education: Taking oral medicines for blood clots (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/86639.html" rel="external">"Patient education: Prothrombin time and INR (PT/INR) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/689.html" rel="external">"Patient education: Warfarin (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/693.html" rel="external">"Patient education: Deep vein thrombosis (DVT) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H46"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Appropriate use</strong> – <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">Vitamin K</a> antagonists ([VKAs] eg, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, <a class="drug drug_general" data-topicid="9159" href="/d/drug information/9159.html" rel="external">acenocoumarol</a>, phenprocoumon, fluindione) have a variety of indications for prophylaxis and treatment of thromboembolic disease, especially prosthetic heart valves and antiphospholipid syndrome. For most patients with venous thromboembolism (VTE) or atrial fibrillation, a direct oral anticoagulant (DOAC) is preferred. The improved safety profile of DOACs over warfarin is particularly relevant for individuals ≥65 years, especially those with other bleeding risk factors. However, there is a large body of experience with VKAs, and these agents may sometimes be preferred due to lower cost, extremes of body weight, severely impaired kidney or liver function, need to monitor adherence, or patient preference. (See <a class="local">'Indications and contraindications'</a> above and <a class="local">'Advantages and disadvantages'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Baseline testing</strong> – Prior to starting <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, patients should have a baseline complete blood count (CBC) with platelet count, prothrombin time (PT), partial thromboplastin time (aPTT), and creatinine. Liver function tests may be helpful in some patients, and females of childbearing potential should have a human chorionic gonadotropin (HCG) test. We suggest not using pharmacogenomic testing to guide warfarin dosing (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Baseline testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial dosing</strong> – For most patients initiating <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> therapy, we suggest an initial dose of ≤5 mg daily for the first two days rather than higher "loading" doses (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). We generally use 5 mg for most healthy adults but might use a lower dose (eg, 2.5 mg daily, 5 mg alternating with 2.5 mg) for females older than 70, males older than 80, or those who are frail, malnourished, have liver or kidney disease, heart failure, or are receiving a medication known to increase warfarin sensitivity  (<a class="graphic graphic_table graphicRef62697" href="/d/graphic/62697.html" rel="external">table 6</a>). An automated dosing calculator is available at <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.warfarindosing.org%2FSource%2FHome.aspx&amp;token=emmKyy2yDV4z6%2BKYhFJGF1QvqYcRg3ihEecLEH8wGnw54o%2BynUAbEvUweM26kX3gpWLkreGJe23muZwsBUqs3Q%3D%3D&amp;TOPIC_ID=1334" target="_blank">www.WarfarinDosing.org/Source/Home.aspx</a>. Dosing on subsequent days is guided by the PT/international normalized ratio (INR) value  (<a class="graphic graphic_table graphicRef101683" href="/d/graphic/101683.html" rel="external">table 4</a>). (See <a class="local">'Initial dosing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance dosing</strong> – Maintenance doses of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> vary significantly among patients; a reasonable approach to adjusting warfarin dosing is outlined in the table  (<a class="graphic graphic_table graphicRef87435" href="/d/graphic/87435.html" rel="external">table 5</a>). In general, management through an anticoagulation clinic or self-management is associated with better outcomes than individual clinician management in the community. The choice between these options will depend on clinician and patient resources and preferences. (See <a class="local">'Establishing a maintenance dose'</a> above and <a class="local">'Outpatient management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> is monitored using the PT/INR, which correlates well with clinical outcomes. Monitoring intervals depend on the stability of previous measurements and changes in clinical status. (See <a class="local">'Monitoring (PT/INR)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Improving efficacy</strong> – Patient education includes information about the effects of certain foods, smoking, and alcohol intake on INR control and how to minimize INR perturbations, as well as awareness about bleeding risk and pregnancy considerations. For patients with unexplained poor INR control, it is important to confirm that the VKA is being taken as prescribed and that the patient does not have <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> deficiency. (See <a class="local">'Counseling and patient education'</a> above and <a class="local">'Poor INR control/vitamin K supplementation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Switching anticoagulants</strong> – It may be appropriate to overlap anticoagulants when changing from one agent to another to another, especially in patients with high thromboembolic risk. Recommendations for switching between oral anticoagulants are summarized above and discussed in more detail in a separate topic review. (See <a class="local">'Transitioning between anticoagulants/bridging'</a> above and  <a class="medical medical_review" href="/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Transitioning between anticoagulants'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bleeding</strong> – Risk factors for VKA-associated bleeding and supratherapeutic INR, and recommendations for minimizing and managing these risks, are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants"</a> and  <a class="medical medical_review" href="/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR"</a> and  <a class="medical medical_review" href="/d/html/1325.html" rel="external">"Reversal of anticoagulation in intracranial hemorrhage"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other complications</strong> – Additional complications of VKAs include skin necrosis (typically in the setting of protein C deficiency), cholesterol embolization ("blue toe syndrome"), teratogenicity, vascular calcification, and allergic reactions. <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> can also interfere with some thrombophilia testing  (<a class="graphic graphic_table graphicRef76966" href="/d/graphic/76966.html" rel="external">table 3</a>). (See <a class="local">'Complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Special situations</strong> – Management in individuals attempting conception, perioperative management, older individuals, and individuals with a bleeding episode are presented above and in separate linked topic reviews. (See <a class="local">'Special situations'</a> above.)</p><p></p><p class="headingAnchor" id="H453730954"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Karen A Valentine, MD, PhD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Stergiopoulos K, Brown DL. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. JAMA Intern Med 2014; 174:1330.</a></li><li><a class="nounderline abstract_t">Belley-Cote EP, Hanif H, D'Aragon F, et al. Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. A systematic review and meta-analysis. Thromb Haemost 2015; 114:768.</a></li><li><a class="nounderline abstract_t">Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e152S.</a></li><li><a class="nounderline abstract_t">Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997; 126:133.</a></li><li><a class="nounderline abstract_t">Crowther MA, Ginsberg JB, Kearon C, et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med 1999; 159:46.</a></li><li><a class="nounderline abstract_t">Farahmand S, Saeedi M, Seyed Javadi HH, Khashayar P. High doses of warfarin are more beneficial than its low doses in patients with deep vein thrombosis. Am J Emerg Med 2011; 29:1222.</a></li><li><a class="nounderline abstract_t">Kovacs MJ, Rodger M, Anderson DR, et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med 2003; 138:714.</a></li><li><a class="nounderline abstract_t">Cushman M, Booth SL, Possidente CJ, et al. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br J Haematol 2001; 112:572.</a></li><li><a class="nounderline abstract_t">Lubetsky A, Dekel-Stern E, Chetrit A, et al. Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. Thromb Haemost 1999; 81:396.</a></li><li><a class="nounderline abstract_t">Khan T, Wynne H, Wood P, et al. Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. Br J Haematol 2004; 124:348.</a></li><li><a class="nounderline abstract_t">Franco V, Polanczyk CA, Clausell N, Rohde LE. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med 2004; 116:651.</a></li><li><a class="nounderline abstract_t">Limdi NA, Beasley TM, Baird MF, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009; 20:912.</a></li><li><a class="nounderline abstract_t">Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol 2011; 154:311.</a></li><li><a class="nounderline abstract_t">Garcia P, Ruiz W, Loza Munárriz C. Warfarin initiation nomograms for venous thromboembolism. Cochrane Database Syst Rev 2016; 2016:CD007699.</a></li><li><a class="nounderline abstract_t">Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:160S.</a></li><li><a class="nounderline abstract_t">Poller L, Keown M, Ibrahim S, et al. An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. J Thromb Haemost 2008; 6:935.</a></li><li><a class="nounderline abstract_t">Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 84:326.</a></li><li><a class="nounderline abstract_t">Gage BF, Fihn SD, White RH. Management and dosing of warfarin therapy. Am J Med 2000; 109:481.</a></li><li><a class="nounderline abstract_t">Barnes GD, Froehlich JB. Anticoagulation: a pathway to clinical effectiveness. Am J Med 2009; 122:126.</a></li><li><a class="nounderline abstract_t">Kim YK, Nieuwlaat R, Connolly SJ, et al. Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. J Thromb Haemost 2010; 8:101.</a></li><li><a class="nounderline abstract_t">Le Gal G, Carrier M, Tierney S, et al. Prediction of the warfarin maintenance dose after completion of the 10 mg initiation nomogram: do we really need genotyping? J Thromb Haemost 2010; 8:90.</a></li><li><a class="nounderline abstract_t">Borgman MP, Pendleton RC, McMillin GA, et al. Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation. Thromb Haemost 2012; 108:561.</a></li><li><a class="nounderline abstract_t">Van Spall HG, Wallentin L, Yusuf S, et al. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation 2012; 126:2309.</a></li><li><a class="nounderline abstract_t">Jones M, McEwan P, Morgan CL, et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005; 91:472.</a></li><li><a class="nounderline abstract_t">Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376:975.</a></li><li><a class="nounderline abstract_t">Garrison SR, Green L, Kolber MR, et al. The Effect of Warfarin Administration Time on Anticoagulation Stability (INRange): A Pragmatic Randomized Controlled Trial. Ann Fam Med 2020; 18:42.</a></li><li><a class="nounderline abstract_t">Rose AJ, Ozonoff A, Berlowitz DR, et al. Warfarin dose management affects INR control. J Thromb Haemost 2009; 7:94.</a></li><li><a class="nounderline abstract_t">Rose AJ. Improving the management of warfarin may be easier than we think. Circulation 2012; 126:2277.</a></li><li><a class="nounderline abstract_t">Lefrère JJ, Guyon F, Horellou MH, et al. [Resistance to vitamin K antagonists. 6 cases]. Ann Med Interne (Paris) 1986; 137:384.</a></li><li><a class="nounderline abstract_t">Hallak HO, Wedlund PJ, Modi MW, et al. High clearance of (S)-warfarin in a warfarin-resistant subject. Br J Clin Pharmacol 1993; 35:327.</a></li><li><a class="nounderline abstract_t">Hulse ML. Warfarin resistance: diagnosis and therapeutic alternatives. Pharmacotherapy 1996; 16:1009.</a></li><li><a class="nounderline abstract_t">Limdi NA, Limdi MA, Cavallari L, et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis 2010; 56:823.</a></li><li><a class="nounderline abstract_t">Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2018; 2:3257.</a></li><li><a class="nounderline abstract_t">Metlay JP, Hennessy S, Localio AR, et al. Patient reported receipt of medication instructions for warfarin is associated with reduced risk of serious bleeding events. J Gen Intern Med 2008; 23:1589.</a></li><li><a class="nounderline abstract_t">Anderson RJ. Cost analysis of a managed care decentralized outpatient pharmacy anticoagulation service. J Manag Care Pharm 2004; 10:159.</a></li><li><a class="nounderline abstract_t">Saokaew S, Permsuwan U, Chaiyakunapruk N, et al. Effectiveness of pharmacist-participated warfarin therapy management: a systematic review and meta-analysis. J Thromb Haemost 2010; 8:2418.</a></li><li><a class="nounderline abstract_t">Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998; 158:1641.</a></li><li><a class="nounderline abstract_t">Gray DR, Garabedian-Ruffalo SM, Chretien SD. Cost-justification of a clinical pharmacist-managed anticoagulation clinic. Ann Pharmacother 2007; 41:496.</a></li><li><a class="nounderline abstract_t">Aziz F, Corder M, Wolffe J, Comerota AJ. Anticoagulation monitoring by an anticoagulation service is more cost-effective than routine physician care. J Vasc Surg 2011; 54:1404.</a></li><li><a class="nounderline abstract_t">Connock M, Stevens C, Fry-Smith A, et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess 2007; 11:iii.</a></li><li><a class="nounderline abstract_t">Jowett S, Bryan S, Murray E, et al. Patient self-management of anticoagulation therapy: a trial-based cost-effectiveness analysis. Br J Haematol 2006; 134:632.</a></li><li><a class="nounderline abstract_t">Jennings I, Kitchen D, Keeling D, et al. Patient self-testing and self-management of oral anticoagulation with vitamin K antagonists: guidance from the British Committee for Standards in Haematology. Br J Haematol 2014; 167:600.</a></li><li><a class="nounderline abstract_t">Lee H, Kim HJ, Chang HW, et al. Development of a system to support warfarin dose decisions using deep neural networks. Sci Rep 2021; 11:14745.</a></li><li><a class="nounderline abstract_t">Zhang F, Liu Y, Ma W, et al. Nonlinear Machine Learning in Warfarin Dose Prediction: Insights from Contemporary Modelling Studies. J Pers Med 2022; 12.</a></li><li><a class="nounderline abstract_t">Jahmunah V, Chen S, Oh SL, et al. Automated warfarin dose prediction for Asian, American, and Caucasian populations using a deep neural network. Comput Biol Med 2023; 153:106548.</a></li><li><a class="nounderline abstract_t">McGuinn TL, Scherr S. Anticoagulation clinic versus a traditional warfarin management model. Nurse Pract 2014; 39:40.</a></li><li><a class="nounderline abstract_t">Manotti C, Moia M, Palareti G, et al. Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). Haematologica 2001; 86:1060.</a></li><li><a class="nounderline abstract_t">Oake N, van Walraven C, Rodger MA, Forster AJ. Effect of an interactive voice response system on oral anticoagulant management. CMAJ 2009; 180:927.</a></li><li><a class="nounderline abstract_t">Louis KM, Martineau J, Rodrigues I, et al. Primary care practices and determinants of optimal anticoagulation management in a collaborative care model. Am Heart J 2010; 159:183.</a></li><li><a class="nounderline abstract_t">Fitzmaurice DA, Hobbs FD, Murray ET, et al. Oral anticoagulation management in primary care with the use of computerized decision support and near-patient testing: a randomized, controlled trial. Arch Intern Med 2000; 160:2343.</a></li><li><a class="nounderline abstract_t">Wilson SJ, Wells PS, Kovacs MJ, et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ 2003; 169:293.</a></li><li><a class="nounderline abstract_t">Poller L, Keown M, Ibrahim S, et al. A multicentre randomised clinical endpoint study of PARMA 5 computer-assisted oral anticoagulant dosage. Br J Haematol 2008; 143:274.</a></li><li><a class="nounderline abstract_t">Wittkowsky AK, Nutescu EA, Blackburn J, et al. Outcomes of oral anticoagulant therapy managed by telephone vs in-office visits in an anticoagulation clinic setting. Chest 2006; 130:1385.</a></li><li><a class="nounderline abstract_t">Tran RJC, Yamzon J, Stewart TL, et al. Effectiveness of Telepharmacy Versus Face-to-Face Anticoagulation Services in the Ambulatory Care Setting: A Systematic Review and Meta-analysis. Ann Pharmacother 2021; 55:1084.</a></li><li><a class="nounderline abstract_t">Siebenhofer A, Berghold A, Sawicki PT. Systematic review of studies of self-management of oral anticoagulation. Thromb Haemost 2004; 91:225.</a></li><li><a class="nounderline abstract_t">Gardiner C, Williams K, Mackie IJ, et al. Patient self-testing is a reliable and acceptable alternative to laboratory INR monitoring. Br J Haematol 2005; 128:242.</a></li><li><a class="nounderline abstract_t">Fitzmaurice DA, Murray ET, McCahon D, et al. Self management of oral anticoagulation: randomised trial. BMJ 2005; 331:1057.</a></li><li><a class="nounderline abstract_t">Siebenhofer A, Rakovac I, Kleespies C, et al. Self-management of oral anticoagulation reduces major outcomes in the elderly. A randomized controlled trial. Thromb Haemost 2008; 100:1089.</a></li><li><a class="nounderline abstract_t">Ryan F, Byrne S, O'Shea S. Randomized controlled trial of supervised patient self-testing of warfarin therapy using an internet-based expert system. J Thromb Haemost 2009; 7:1284.</a></li><li><a class="nounderline abstract_t">Verret L, Couturier J, Rozon A, et al. Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial. Pharmacotherapy 2012; 32:871.</a></li><li><a class="nounderline abstract_t">Nagler M, Raddatz-Müller P, Schmid P, et al. Accuracy of the point-of-care coagulometer CoaguChek XS in the hands of patients. J Thromb Haemost 2013; 11:197.</a></li><li><a class="nounderline abstract_t">Ward A, Tompson A, Fitzmaurice D, et al. Cohort study of Anticoagulation Self-Monitoring (CASM): a prospective study of its effectiveness in the community. Br J Gen Pract 2015; 65:e428.</a></li><li><a class="nounderline abstract_t">Heneghan C, Alonso-Coello P, Garcia-Alamino JM, et al. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006; 367:404.</a></li><li><a class="nounderline abstract_t">Garcia-Alamino JM, Ward AM, Alonso-Coello P, et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev 2010; :CD003839.</a></li><li><a class="nounderline abstract_t">Bloomfield HE, Krause A, Greer N, et al. Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. Ann Intern Med 2011; 154:472.</a></li><li><a class="nounderline abstract_t">Heneghan CJ, Garcia-Alamino JM, Spencer EA, et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev 2016; 7:CD003839.</a></li><li><a class="nounderline abstract_t">Matchar DB, Jacobson A, Dolor R, et al. Effect of home testing of international normalized ratio on clinical events. N Engl J Med 2010; 363:1608.</a></li><li><a class="nounderline abstract_t">Ansell J, Jacobson A, Levy J, et al. Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation. Int J Cardiol 2005; 99:37.</a></li><li><a class="nounderline abstract_t">Dolor RJ, Ruybalid RL, Uyeda L, et al. An evaluation of patient self-testing competency of prothrombin time for managing anticoagulation: pre-randomization results of VA Cooperative Study #481--The Home INR Study (THINRS). J Thromb Thrombolysis 2010; 30:263.</a></li><li><a class="nounderline abstract_t">Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997; 127:177.</a></li><li><a class="nounderline abstract_t">Rose AJ, Ozonoff A, Berlowitz DR, et al. Reexamining the recommended follow-up interval after obtaining an in-range international normalized ratio value: results from the Veterans Affairs study to improve anticoagulation. Chest 2011; 140:359.</a></li><li><a class="nounderline abstract_t">Schulman S, Parpia S, Stewart C, et al. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med 2011; 155:653.</a></li><li><a class="nounderline abstract_t">Fihn SD, McDonell MB, Vermes D, et al. A computerized intervention to improve timing of outpatient follow-up: a multicenter randomized trial in patients treated with warfarin. National Consortium of Anticoagulation Clinics. J Gen Intern Med 1994; 9:131.</a></li><li><a class="nounderline abstract_t">Pengo V, Barbero F, Biasiolo A, et al. A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment. Am J Clin Pathol 2003; 120:944.</a></li><li><a class="nounderline abstract_t">Kucher N, Connolly S, Beckman JA, et al. International normalized ratio increase before warfarin-associated hemorrhage: brief and subtle. Arch Intern Med 2004; 164:2176.</a></li><li><a class="nounderline abstract_t">European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333:5.</a></li><li><a class="nounderline abstract_t">White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167:239.</a></li><li><a class="nounderline abstract_t">Oake N, Jennings A, Forster AJ, et al. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ 2008; 179:235.</a></li><li><a class="nounderline abstract_t">Lane DA, Lip GY. Maintaining therapeutic anticoagulation: the importance of keeping "within range". Chest 2007; 131:1277.</a></li><li><a class="nounderline abstract_t">Oake N, Fergusson DA, Forster AJ, van Walraven C. Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ 2007; 176:1589.</a></li><li><a class="nounderline abstract_t">Kaatz S. Determinants and measures of quality in oral anticoagulation therapy. J Thromb Thrombolysis 2008; 25:61.</a></li><li><a class="nounderline abstract_t">Phillips KW, Ansell J. Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management. Expert Rev Cardiovasc Ther 2008; 6:57.</a></li><li><a class="nounderline abstract_t">ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367:1903.</a></li><li><a class="nounderline abstract_t">van Walraven C, Jennings A, Oake N, et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006; 129:1155.</a></li><li><a class="nounderline abstract_t">Mahtani KR, Heneghan CJ, Nunan D, Roberts NW. Vitamin K for improved anticoagulation control in patients receiving warfarin. Cochrane Database Syst Rev 2014; :CD009917.</a></li><li><a class="nounderline abstract_t">Dentali F, Crowther M, Galli M, et al. Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature. Semin Thromb Hemost 2016; 42:671.</a></li><li><a class="nounderline abstract_t">Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 2007; 109:2419.</a></li><li><a class="nounderline abstract_t">Reese AM, Farnett LE, Lyons RM, et al. Low-dose vitamin K to augment anticoagulation control. Pharmacotherapy 2005; 25:1746.</a></li><li class="breakAll">http://www.gnc.com/product/index.jsp?productId=2133377 (Accessed on May 24, 2010).</li><li><a class="nounderline abstract_t">Oskarsdottir AR, Gudmundsdottir BR, Jensdottir HM, et al. Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study. Blood 2021; 137:2745.</a></li><li><a class="nounderline abstract_t">Witt DM. A better way to monitor warfarin therapy? Blood 2021; 137:2713.</a></li><li><a class="nounderline abstract_t">Cairns JA, Weitz JI. Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding. Am Heart J 2015; 169:1.</a></li><li><a class="nounderline abstract_t">Granger CB, Lopes RD, Hanna M, et al. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J 2015; 169:25.</a></li><li><a class="nounderline abstract_t">Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e44S.</a></li><li><a class="nounderline abstract_t">Halkin H, Shapiro J, Kurnik D, et al. Increased warfarin doses and decreased international normalized ratio response after nationwide generic switching. Clin Pharmacol Ther 2003; 74:215.</a></li><li><a class="nounderline abstract_t">Milligan PE, Banet GA, Waterman AD, et al. Substitution of generic warfarin for Coumadin in an HMO setting. Ann Pharmacother 2002; 36:764.</a></li><li><a class="nounderline abstract_t">Witt DM, Tillman DJ, Evans CM, et al. Evaluation of the clinical and economic impact of a brand name-to-generic warfarin sodium conversion program. Pharmacotherapy 2003; 23:360.</a></li><li><a class="nounderline abstract_t">Meyering C, Howard T. Hypercoagulability in athletes. Curr Sports Med Rep 2004; 3:77.</a></li><li><a class="nounderline abstract_t">Mellwig KP, van Buuren F, Gohlke-Baerwolf C, Bjørnstad HH. Recommendations for the management of individuals with acquired valvular heart diseases who are involved in leisure-time physical activities or competitive sports. Eur J Cardiovasc Prev Rehabil 2008; 15:95.</a></li><li><a class="nounderline abstract_t">Bauer KA. Coumarin-induced skin necrosis. Arch Dermatol 1993; 129:766.</a></li><li><a class="nounderline abstract_t">Teepe RG, Broekmans AW, Vermeer BJ, et al. Recurrent coumarin-induced skin necrosis in a patient with an acquired functional protein C deficiency. Arch Dermatol 1986; 122:1408.</a></li><li><a class="nounderline abstract_t">Haran MZ, Lichman I, Berebbi A, et al. Unbalanced protein S deficiency due to warfarin treatment as a possible cause for thrombosis. Br J Haematol 2007; 139:310.</a></li><li><a class="nounderline abstract_t">Bols A, Nevelsteen A, Verhaeghe R. Atheromatous embolization precipitated by oral anticoagulants. Int Angiol 1994; 13:271.</a></li><li><a class="nounderline abstract_t">Rauh G, Spengel FA. Blue toe syndrome after initiation of low-dose oral anticoagulation. Eur J Med Res 1998; 3:278.</a></li><li><a class="nounderline abstract_t">Hyman BT, Landas SK, Ashman RF, et al. Warfarin-related purple toes syndrome and cholesterol microembolization. Am J Med 1987; 82:1233.</a></li><li><a class="nounderline abstract_t">Koos R, Mahnken AH, Mühlenbruch G, et al. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am J Cardiol 2005; 96:747.</a></li><li><a class="nounderline abstract_t">Koos R, Krueger T, Westenfeld R, et al. Relation of circulating Matrix Gla-Protein and anticoagulation status in patients with aortic valve calcification. Thromb Haemost 2009; 101:706.</a></li><li><a class="nounderline abstract_t">Rennenberg RJ, van Varik BJ, Schurgers LJ, et al. Chronic coumarin treatment is associated with increased extracoronary arterial calcification in humans. Blood 2010; 115:5121.</a></li><li><a class="nounderline abstract_t">Weijs B, Blaauw Y, Rennenberg RJ, et al. Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J 2011; 32:2555.</a></li><li><a class="nounderline abstract_t">Kruis-de Vries MH, Stricker BH, Coenraads PJ, Nater JP. Maculopapular rash due to coumarin derivatives. Dermatologica 1989; 178:109.</a></li><li><a class="nounderline abstract_t">Torn M, Bollen WL, van der Meer FJ, et al. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med 2005; 165:1527.</a></li><li><a class="nounderline abstract_t">Wieloch M, Själander A, Frykman V, et al. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J 2011; 32:2282.</a></li><li><a class="nounderline abstract_t">Sudlow CM, Rodgers H, Kenny RA, Thomson RG. Service provision and use of anticoagulants in atrial fibrillation. BMJ 1995; 311:558.</a></li><li><a class="nounderline abstract_t">Lip GY, Golding DJ, Nazir M, et al. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br J Gen Pract 1997; 47:285.</a></li><li><a class="nounderline abstract_t">Gurwitz JH, Monette J, Rochon PA, et al. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med 1997; 157:978.</a></li><li><a class="nounderline abstract_t">Brass LM, Krumholz HM, Scinto JD, et al. Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation. Arch Intern Med 1998; 158:2093.</a></li><li><a class="nounderline abstract_t">By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2023; 71:2052.</a></li><li><a class="nounderline abstract_t">Routledge PA, Chapman PH, Davies DM, Rawlins MD. Factors affecting warfarin requirements. A prospective population study. Eur J Clin Pharmacol 1979; 15:319.</a></li><li><a class="nounderline abstract_t">Eccles JT. Control of warfarin therapy in the elderly. Age Ageing 1975; 4:161.</a></li><li><a class="nounderline abstract_t">Froom P, Miron E, Barak M. Oral anticoagulants in the elderly. Br J Haematol 2003; 120:526.</a></li><li><a class="nounderline abstract_t">Shepherd AM, Hewick DS, Moreland TA, Stevenson IH. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol 1977; 4:315.</a></li><li><a class="nounderline abstract_t">Schwartz JB, Kane L, Moore K, Wu AH. Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin. J Am Med Dir Assoc 2011; 12:633.</a></li></ol></div><div id="topicVersionRevision">Topic 1334 Version 113.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24935087" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26158747" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315259" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9005747" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9892329" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A randomized trial comparing 5-mg and 10-mg warfarin loading doses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21035980" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : High doses of warfarin are more beneficial than its low doses in patients with deep vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12729425" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11260056" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The association of vitamin K status with warfarin sensitivity at the onset of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10102468" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Vitamin K intake and sensitivity to warfarin in patients consuming regular diets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14717783" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15121490" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19225037" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Kidney function influences warfarin responsiveness and hemorrhagic complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21671894" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Guidelines on oral anticoagulation with warfarin - fourth edition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26822633" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Warfarin initiation nomograms for venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574265" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18489430" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18305455" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11042238" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Management and dosing of warfarin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19185085" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Anticoagulation: a pathway to clinical effectiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19840361" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19874475" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prediction of the warfarin maintenance dose after completion of the 10 mg initiation nomogram: do we really need genotyping?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22836303" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23027801" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15772203" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20801496" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31937532" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The Effect of Warfarin Administration Time on Anticoagulation Stability (INRange): A Pragmatic Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18983486" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Warfarin dose management affects INR control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23027800" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Improving the management of warfarin may be easier than we think.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3813270" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : [Resistance to vitamin K antagonists. 6 cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8471414" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : High clearance of (S)-warfarin in a warfarin-resistant subject.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8947972" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Warfarin resistance: diagnosis and therapeutic alternatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20709439" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Warfarin dosing in patients with impaired kidney function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30482765" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18618191" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Patient reported receipt of medication instructions for warfarin is associated with reduced risk of serious bleeding events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15032565" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cost analysis of a managed care decentralized outpatient pharmacy anticoagulation service.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20831620" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effectiveness of pharmacist-participated warfarin therapy management: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9701098" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17341522" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cost-justification of a clinical pharmacist-managed anticoagulation clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21741791" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Anticoagulation monitoring by an anticoagulation service is more cost-effective than routine physician care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17903392" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16938120" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Patient self-management of anticoagulation therapy: a trial-based cost-effectiveness analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25141928" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Patient self-testing and self-management of oral anticoagulation with vitamin K antagonists: guidance from the British Committee for Standards in Haematology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34285309" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Development of a system to support warfarin dose decisions using deep neural networks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35629140" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Nonlinear Machine Learning in Warfarin Dose Prediction: Insights from Contemporary Modelling Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36652867" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Automated warfarin dose prediction for Asian, American, and Caucasian populations using a deep neural network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25225978" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Anticoagulation clinic versus a traditional warfarin management model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11602412" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19398739" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effect of an interactive voice response system on oral anticoagulant management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20152215" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Primary care practices and determinants of optimal anticoagulation management in a collaborative care model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10927732" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Oral anticoagulation management in primary care with the use of computerized decision support and near-patient testing: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12925422" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18759767" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A multicentre randomised clinical endpoint study of PARMA 5 computer-assisted oral anticoagulant dosage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17099014" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Outcomes of oral anticoagulant therapy managed by telephone vs in-office visits in an anticoagulation clinic setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33384017" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Effectiveness of Telepharmacy Versus Face-to-Face Anticoagulation Services in the Ambulatory Care Setting: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14961147" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Systematic review of studies of self-management of oral anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15638860" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Patient self-testing is a reliable and acceptable alternative to laboratory INR monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16216821" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Self management of oral anticoagulation: randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19132235" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Self-management of oral anticoagulation reduces major outcomes in the elderly. A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19496921" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Randomized controlled trial of supervised patient self-testing of warfarin therapy using an internet-based expert system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23033226" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23121888" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Accuracy of the point-of-care coagulometer CoaguChek XS in the hands of patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26077267" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cohort study of Anticoagulation Self-Monitoring (CASM): a prospective study of its effectiveness in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16458764" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Self-monitoring of oral anticoagulation: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20393937" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Self-monitoring and self-management of oral anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21464349" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27378324" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Self-monitoring and self-management of oral anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20961244" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effect of home testing of international normalized ratio on clinical events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15721497" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20628787" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : An evaluation of patient self-testing competency of prothrombin time for managing anticoagulation: pre-randomization results of VA Cooperative Study #481--The Home INR Study (THINRS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9245222" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Monitoring warfarin therapy in patients with lupus anticoagulants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21310837" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Reexamining the recommended follow-up interval after obtaining an in-range international normalized ratio value: results from the Veterans Affairs study to improve anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22084331" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8195911" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A computerized intervention to improve timing of outpatient follow-up: a multicenter randomized trial in patients treated with warfarin. National Consortium of Anticoagulation Clinics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14671984" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15505133" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : International normalized ratio increase before warfarin-associated hemorrhage: brief and subtle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7776995" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17296878" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18663203" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17494777" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Maintaining therapeutic anticoagulation: the importance of keeping "within range".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17515585" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Frequency of adverse events in patients with poor anticoagulation: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17906916" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Determinants and measures of quality in oral anticoagulation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18095907" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16765759" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16685005" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Effect of study setting on anticoagulation control: a systematic review and metaregression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24832594" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Vitamin K for improved anticoagulation control in patients receiving warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27232386" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17110451" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16305294" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Low-dose vitamin K to augment anticoagulation control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16305294" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Low-dose vitamin K to augment anticoagulation control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33512454" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34014293" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : A better way to monitor warfarin therapy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25497240" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25497244" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315269" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12966365" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Increased warfarin doses and decreased international normalized ratio response after nationwide generic switching.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11978149" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Substitution of generic warfarin for Coumadin in an HMO setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12627935" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Evaluation of the clinical and economic impact of a brand name-to-generic warfarin sodium conversion program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14980135" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Hypercoagulability in athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18277193" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Recommendations for the management of individuals with acquired valvular heart diseases who are involved in leisure-time physical activities or competitive sports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8507082" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Coumarin-induced skin necrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3789774" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Recurrent coumarin-induced skin necrosis in a patient with an acquired functional protein C deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17897308" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Unbalanced protein S deficiency due to warfarin treatment as a possible cause for thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7822905" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Atheromatous embolization precipitated by oral anticoagulants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9620888" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Blue toe syndrome after initiation of low-dose oral anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3605140" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Warfarin-related purple toes syndrome and cholesterol microembolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16169351" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19350115" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Relation of circulating Matrix Gla-Protein and anticoagulation status in patients with aortic valve calcification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20354170" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Chronic coumarin treatment is associated with increased extracoronary arterial calcification in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21775389" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2522402" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Maculopapular rash due to coumarin derivatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009869" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Risks of oral anticoagulant therapy with increasing age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21616951" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7663216" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Service provision and use of anticoagulants in atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9219403" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9140268" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Atrial fibrillation and stroke prevention with warfarin in the long-term care setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9801175" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37139824" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : American Geriatrics Society 2023 updated AGS Beers Criteria®for potentially inappropriate medication use in older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/378674" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Factors affecting warfarin requirements. A prospective population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1211301" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Control of warfarin therapy in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12580973" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Oral anticoagulants in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/901699" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Age as a determinant of sensitivity to warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21450231" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
